NYSEAMERICAN : RGNT
Regentis Biomaterials Ltd. — Company profile
Healthcare · Other · Israel
Last price 1.37 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 9.62M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
Regentis Biomaterials Ltd., a regenerative medicine company, develops and commercializes tissue repair solutions in the United States. It offers Gelrin, a platform based on hydrogel matrix of polyethylene glycol diacrylate and denatured fibrinogen for the treatment and regeneration of damaged or diseased tissue; and GelrinC, a cell-free and off-the-shelf hydrogel, which is in Phase II clinical trial for the treatment of cartilage injuries in the knee. The company was incorporated in 2004 and is based in Herzliya, Israel.
Details
| Name | Regentis Biomaterials Ltd. |
| Sector | Healthcare |
| Industry | Medical Instruments & Supplies |
| Employees | 7 |
| Founded | 2004 |
| Ipo Date | 2025-12-04 |
| Ceo | Ehud Geller |
| Country | Israel |
| Exchange | NYSEAMERICAN |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| Ipo Price | 8.00 |
| Isin | IL0012190968 |
| Cusip | 001219096 |
| Cik | 1912966 |
| Sic | 3842 |
Key executives
| Name | Title |
|---|---|
| Dr. Ehud Geller Ph.D. | Chief Executive Officer and Executive Chairman |
| Arie Gordashnikov CPA | Chief Accounting Officer |
| Dr. Dror Seliktar Ph.D. | Co-Founder and Chief Scientific Officer |
| Ori Gon | Chief Financial Officer and Chief Business Officer |
| Dr. Galit Reske Ph.D. | Chief Medical Officer |
Contact
| Address | 60, Medinat Hayehudim, Entrance C, Herzliya, 4676652, Israel |
| Phone | 972 9 960 1917 |
| Website | https://www.regentis.co.il |